Medical; Abortion, Fetus
Conditions
Brief summary
The goal of this study is to examine the effectiveness and feasibility of a mifepristone-misoprostol medical abortion regimen in terminating pregnancies 13-22 weeks in Burkina Faso.
Interventions
DRUGMifepristone
Medication used in conjunction with misoprostol for abortion
DRUGMisoprostol
Medication used in conjunction with mifepristone for abortion
Sponsors
Gynuity Health Projects
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Healthy volunteers
Yes
Inclusion criteria
* Having an ongoing pregnancy of 13-22 weeks gestation * Be willing to undergo surgical completion if necessary * Have no contraindications to study procedures, according to provider * Be willing and able to consent to participate in the study * Be willing to follow study procedures * Respect legal indications for obtaining an abortion
Exclusion criteria
* Known allergy to mifepristone or misoprostol/prostaglandin * Any contraindications to vaginal delivery, including placenta previa * Previous transmural uterine incsion
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Rate of successful abortion | 24 hours | Rate of successful abortion, complete evacuation of foetus and placenta with study drugs, within 24 hours of taking misoprostol |
Countries
Burkina Faso
Contacts
Primary ContactMeighan Tarnagada, MPH
Backup ContactAyisha Diop, MS
Outcome results
None listed